Biologics Market
Biologics Market Overview
The report is titled ‘Biologics Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the biologics market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The biologics market is expected to grow at a significant rate in the near future.
The biologics market is estimated to reach at a value of US 339.3 Bn by the end of 2022 and expected to reach at a value of US$ 610.2 Bn by 2030 with a significant CAGR of 7.6%.
Biologics Introduction
Biologics, or a biologic drug, is a substance that is made from living creatures or comprise elements of living creatures. Biologic drugs consist of an extensive range of by-products obtained from microorganisms, animals, and humans by the usage of biotechnology. The various kinds of biologic drugs or biologics comprises blood and its components, cells, vaccines, genes, allergens, tissues, and recombinant proteins.
Biologics Market Dynamics
A biologic is created in a life system including animal or plant cells, or microorganisms that are majorly used to impede, diagnose, and to treat, or cure a wide range of illnesses such as chronic kidney disease, cancer, infectious diseases, and autoimmune disorders.
In the present times, the rising incidence of chronic diseases such as autoimmune diseases, diabetes, and cancer among the population owing to the lethargic lifestyle, poor diet, and desk-bound jobs is mainly encouraging the demand of biologics in the global market, thus propelling the growth of the global biologics market.
In addition to that, the constant research activities, across the world, resulting in therapeutic diversification of biologics across varied indicators such as allergic conditions, asthma, dyslipidemia and other non-conventional disease areas, is another major factor that is driving the overall growth of the global biologics industry.
However, due to the inadequacy of reimbursements for biologics as well as heavy cost, there is a shortage of biologics especially in mid to low income economies around the world. Such factors may hold back the growth of the global biologics market over the coming years.
Biologics Market Segmentation
The global biologics market is segmented on the basis of drug class, therapeutic application, distribution channel, and regions. On the basis of the drug class, the biologics market is segmented into Monoclonal Antibody, Vaccine, Recombinant Insulin, Human Growth Hormone, Blood Factor, Fusion Protein, Erythropoietin, Recombinant Enzyme, Interferon, Colony-stimulating Factor, Cell Therapy, Gene Therapy, Oligonucleotides and Others (Peptide, Botulinum Toxin, and Others). Based on therapeutic application, the market is bifurcated into Oncology, Metabolic Disorders, Autoimmune/Immunologic Diseases, Ophthalmic Diseases, Inflammatory Bowel Diseases (IBDs), Respiratory Disorders, Neurological Disorders, Musculoskeletal Disorders (MSDs), Cardiovascular Diseases (CVDs), Infectious Diseases, and Others. On the basis of the distribution channel, the market is categorized into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies.
The research report classifies the global biologics market based on drug class, therapeutic application, distribution channel, and regions.
By Drug Class
Monoclonal Antibody
Vaccine
Recombinant Insulin
Human Growth Hormone
Blood Factor
Fusion Protein
Erythropoietin
Recombinant Enzyme
Interferon
Colony-stimulating Factor
Cell Therapy
Gene Therapy
Oligonucleotides
By Therapeutic Application
Oncology
Metabolic Disorders
Autoimmune/Immunologic Diseases
Ophthalmic Diseases
Inflammatory Bowel Diseases (IBDs)
Respiratory Disorder
Neurological Disorders
Musculoskeletal Disorders (MSDs)
Cardiovascular Diseases (CVDs)
Infectious Diseases
Others
By Distribution Channels
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
Latin America
Africa
Europe
Asia Pacific
Middle East
Biologics Market Key Players
The global biologics market is dominated by Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc., among others.
MMC Overview on Biologics Market Report
The non-identical approach of Reports and Insights stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give a better opportunity for the customers to put their effort.
A research report on the biologics market by Reports and Insights is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that support the market and the factors that are acting as impedance for the growth of the market.
Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.
Factors that are benchmarked while estimating the market
Various factors that are benchmarked while estimating the market growth includes (but not restricted to):
New product designs and launches
Current product compliance
Reimbursement
Concerns for use of biologics
Advantages of biologics
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to make informed decisions.
A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.
To learn more about this report, request a free sample copy
1. Global Biologics Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Biologics Market Overview
2.1. Introduction
2.1.1. Introduction
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Biologics Market Snapshot
2.4. Global Biologics Market Size And Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast And Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Biologics Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Porter’s Five Forces Model
2.7. SWOT Analysis
3. Biologics Assessment and Analysis
3.1. Biologics Impact Analysis
3.2. Actions to encourage use of Biologics
3.3. Biologics Promotional Strategy Recommendation
3.4. Road Map Analysis
3.5. GAP Analysis
3.6. Potential Analysis
4. Covid-19 Impact on Biologics Market
4.1. Impact Analysis of Covid-19 on the global Biologics market
4.2. Effect On Value Chain
4.3. Business Impact W.R.T Revenue
4.4. Fluctuation In Production
4.5. Volatility In Price
4.6. Effect On The Overall Trade
4.7. Market Impact Analysis In 2020 (Quarter Wise)
5. Global Biologics Market, By Drug Class
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Drug Class
5.1.2. BPS Analysis, By Drug Class
5.2. Market Revenue (US$Mn) and Forecast, By Drug Class
5.2.1. Monoclonal Antibody
5.2.2. Vaccine
5.2.3. Recombinant Insulin
5.2.4. Human Growth Hormone
5.2.5. Blood Factor
5.2.6. Fusion Protein
5.2.7. Erythropoietin
5.2.8. Recombinant Enzyme
5.2.9. Interferon
5.2.10. Colony-stimulating Factor
5.2.11. Cell Therapy
5.2.12. Gene Therapy
5.2.13. Oligonucleotides
5.3. Global Biologics Market Attractiveness Index, By Drug Class
6. Global Biologics Market, By Therapeutic Application
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Therapeutic Application
6.1.2. BPS Analysis, By Therapeutic Application
6.2. Market Revenue (US$Mn) and Forecast, By Therapeutic Application
6.2.1. Oncology
6.2.2. Metabolic Disorders
6.2.3. Autoimmune/Immunologic Diseases
6.2.4. Ophthalmic Diseases
6.2.5. Inflammatory Bowel Diseases (IBDs)
6.2.6. Respiratory Disorder
6.2.7. Neurological Disorders
6.2.8. Musculoskeletal Disorders (MSDs)
6.2.9. Cardiovascular Diseases (CVDs)
6.2.10. Infectious Diseases
6.2.11. Others
6.3. Global Biologics Market Attractiveness Index, By Therapeutic Application
7. Global Biologics Market, By Distribution Channel
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Distribution Channel
7.1.2. BPS Analysis, By Distribution Channel
7.2. Market Revenue (US$Mn) and Forecast, By Distribution Channel
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.3. Global Biologics Market Attractiveness Index, By Distribution Channel
8. Global Biologics Market, By Region
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Region
8.1.2. BPS Analysis, By Region
8.2. Market Revenue (US$Mn) and Forecast, By Region
8.2.1. North America
8.2.2. Latin America
8.2.3. Europe
8.2.4. Asia Pacific
8.2.5. Middle East
8.2.6. Africa
8.3. Global Biologics Market Attractiveness Index, By Region
9. North America Biologics Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market Revenue (US$Mn) and Forecast, By Country
9.2.1. U.S. Biologics Market
9.2.2. Canada Biologics Market
9.3. North America Biologics Market, By Drug Class
9.3.1. Grade III A
9.3.2. Grade III
9.3.3. Grade III B
9.3.4. Grade IV
9.4. North America Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application
9.4.1. Transparent
9.4.2. Opaque
9.5. North America Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel
9.5.1. Riot Shields
9.5.2. Helmet Visors
9.5.3. Vehicular Bulletproofing
9.6. North America Biologics Market Attractiveness Index
9.6.1. By Country
9.6.2. By Drug Class
9.6.3. By Therapeutic Application
9.6.4. By Distribution Channel
10. Latin America Biologics Market Analysis and Forecast, 2020–2028
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. Brazil Biologics Market
10.2.2. Mexico Biologics Market
10.2.3. Rest Of Latin America Biologics Market
10.3. Latin America Biologics Market, By Drug Class
10.3.1. Grade III A
10.3.2. Grade III
10.3.3. Grade III B
10.3.4. Grade IV
10.4. Latin America Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application
10.4.1. Transparent
10.4.2. Opaque
10.5. Latin America Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel
10.5.1. Riot Shields
10.5.2. Helmet Visors
10.5.3. Vehicular Bulletproofing
10.6. Latin America Biologics Market Attractiveness Index
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Therapeutic Application
10.6.4. By Distribution Channel
11. Europe Biologics Market Analysis and Forecast, 2020–2028
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. U.K. Biologics Market
11.2.2. Germany Biologics Market
11.2.3. Italy Biologics Market
11.2.4. France Biologics Market
11.2.5. Spain Biologics Market
11.2.6. Russia Biologics Market
11.2.7. Rest Of Europe Biologics Market
11.3. Europe Biologics Market, By Drug Class
11.3.1. Grade III A
11.3.2. Grade III
11.3.3. Grade III B
11.3.4. Grade IV
11.4. Europe Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application
11.4.1. Transparent
11.4.2. Opaque
11.5. Europe Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel
11.5.1. Riot Shields
11.5.2. Helmet Visors
11.5.3. Vehicular Bulletproofing
11.6. Europe Biologics Market Attractiveness Index
11.6.1. By Country
11.6.2. By Drug Class
11.6.3. By Therapeutic Application
11.6.4. By Distribution Channel
12. Asia Pacific Biologics Market Analysis and Forecast, 2020–2028
12.1. Introduction
12.1.1. Annual Growth Rate Comparison, By Country
12.1.2. BPS Analysis, By Country
12.2. Market (US$Mn) Forecast, By Country
12.2.1. China Biologics Market
12.2.2. India Biologics Market
12.2.3. Japan Biologics Market
12.2.4. Australia and New Zealand Biologics Market
12.2.5. South Korea Biologics Market
12.2.6. Rest of Asia Pacific Biologics Market
12.3. Asia Pacific Biologics Market, By Drug Class
12.3.1. Grade III A
12.3.2. Grade III
12.3.3. Grade III B
12.3.4. Grade IV
12.4. Asia Pacific Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application
12.4.1. Transparent
12.4.2. Opaque
12.5. Asia Pacific Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel
12.5.1. Riot Shields
12.5.2. Helmet Visors
12.5.3. Vehicular Bulletproofing
12.6. Asia Pacific Biologics Market Attractiveness Index
12.6.1. By Country
12.6.2. By Drug Class
12.6.3. By Therapeutic Application
12.6.4. By Distribution Channel
13. Middle East Biologics Market Analysis and Forecast, 2020–2028
13.1. Introduction
13.1.1. Annual Growth Rate Comparison, By Country
13.1.2. BPS Analysis, By Country
13.2. Market (US$Mn) Forecast, By Country
13.2.1. GCC Countries Biologics Market
13.2.2. Israel Biologics Market
13.2.3. Rest Of Middle East Biologics Market
13.3. Middle East Biologics Market, By Drug Class
13.3.1. Grade III A
13.3.2. Grade III
13.3.3. Grade III B
13.3.4. Grade IV
13.4. Middle East Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application
13.4.1. Transparent
13.4.2. Opaque
13.5. Middle East Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel
13.5.1. Riot Shields
13.5.2. Helmet Visors
13.5.3. Vehicular Bulletproofing
13.6. Middle East Biologics Market Attractiveness Index
13.6.1. By Country
13.6.2. By Drug Class
13.6.3. By Therapeutic Application
13.6.4. By Distribution Channel
14. Africa Biologics Market Analysis and Forecast, 2020–2028
14.1. Introduction
14.1.1. Annual Growth Rate Comparison, By Country
14.1.2. BPS Analysis, By Country
14.2. Market (US$Mn) Forecast, By Country
14.2.1. South Africa Countries Biologics Market
14.2.2. Egypt Biologics Market
14.2.3. North Africa Biologics Market
14.2.4. Rest of Africa Biologics Market
14.3. Africa Biologics Market, By Drug Class
14.3.1. Grade III A
14.3.2. Grade III
14.3.3. Grade III B
14.3.4. Grade IV
14.4. Africa Biologics Market Revenue (US$Mn) and Forecast, By Therapeutic Application
14.4.1. Transparent
14.4.2. Opaque
14.5. Africa Biologics Market Revenue (US$Mn) and Forecast, By Distribution Channel
14.5.1. Riot Shields
14.5.2. Helmet Visors
14.5.3. Vehicular Bulletproofing
14.6. Africa Biologics Market Attractiveness Index
14.6.1. By Country
14.6.2. By Drug Class
14.6.3. By Therapeutic Application
14.6.4. By Distribution Channel
15. Competitive Landscape
15.1. Company Profiles
15.1.1. Bristol-Myers Squibb Company (BMS)
15.1.1.1. Company Overview
15.1.1.2. Financial Overview
15.1.1.3. Key Developments
15.1.1.4. Strategies
15.1.1.5. Product Analysis
15.1.2. Merck & Co., Inc.
15.1.3. Roche AG
15.1.4. Merck KGaA
15.1.5. AstraZeneca Plc
15.1.6. Regeneron Pharmaceuticals, Inc
15.1.7. Novartis International AG
15.1.8. Pfizer Inc.
15.1.9. Amgen, Inc.
15.1.10. AbbVie, Inc.
15.1.11. Sanofi S.A.
15.1.12. Eli Lilly & Company
15.1.13. Novo Nordisk A/S
15.1.14. Johnson & Johnson
15.1.15. GlaxoSmithKline Plc
15.1.16. Teva Pharmaceutical Industries Ltd.
15.1.17. Ipsen S.A.
15.1.18. Allergan Plc.
16. Acronyms
Select License Type
Frequently Asked Questions
The biologics market is estimated to reach at a value of US 339.3 Bn by the end of 2022 and expected to reach at a value of US$ 610.2 Bn by 2030 with a significant CAGR of 7.6%.
The base year for the report is 2021 in biologics market.
The research report classifies the global biologics market based on drug class, therapeutic application, distribution channel, and regions.
Bristol-Myers Squibb Company (BMS), Merck & Co., Inc., Roche AG, Merck KGaA, AstraZeneca Plc, Regeneron Pharmaceuticals, Inc, Novartis International AG, Pfizer, Inc., Amgen, Inc., AbbVie, Inc., Sanofi S.A., Eli Lilly & Company, Novo Nordisk A/S, Johnson & Johnson, GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd., Ipsen S.A., and Allergan Plc are the key participating players in the market
